ESMO Expert Report on antibody drug conjugates in the management of urothelial cancer @ASCO GU 2022 European Society for Medical Oncology (ESMO) 6:28 2 years ago 379 Далее Скачать
Urothelial carcinoma trial data presented at ASCO GU 2022 VJOncology 4:00 2 years ago 69 Далее Скачать
Breakthroughs in urothelial cancer treatment at ESMO 2023 VJOncology 3:38 1 year ago 438 Далее Скачать
Improving Patient Outcomes in Urothelial Carcinoma With Novel Antibody–Drug Conjugates PeerView Oncology 40:12 2 years ago 168 Далее Скачать
Advances in antibody-drug conjugates for breast cancer at ESMO 2022 VJOncology 2:00 2 years ago 158 Далее Скачать
Expert Report on latest data in the management of metastatic prostate cancer from ASCO 2022 European Society for Medical Oncology (ESMO) 4:36 2 years ago 895 Далее Скачать
What’s next for antibody drug conjugates in urothelial carcinoma? VJOncology 1:58 10 months ago 89 Далее Скачать
The future of antibody-drug conjugates in urothelial cancer VJOncology 2:30 10 months ago 95 Далее Скачать
The future of antibody-drug conjugates in urothelial carcinoma VJOncology 1:39 2 months ago 51 Далее Скачать
Simon Crabb and Petros Grivas on the most interesting trials presented at ASCO GU 2022. Springer Healthcare IME 26:44 2 years ago 179 Далее Скачать
Expert video report on Urothelial Carcinoma from 2021 Genitourinary Cancers Symposium European Society for Medical Oncology (ESMO) 6:36 3 years ago 616 Далее Скачать
Novel combined ADCs in metastatic urothelial carcinoma: insights from ESMO 2023 VJOncology 0:38 1 year ago 65 Далее Скачать
What are the latest biomarkers for urothelial carcinoma? VJOncology 0:52 10 months ago 130 Далее Скачать
Utilizing antibody-drug conjugates in the treatment of metastatic urothelial carcinoma VJOncology 1:39 1 year ago 74 Далее Скачать
Where do ADCs fit in the treatment landscape of urothelial carcinoma? VJOncology 0:54 11 months ago 47 Далее Скачать
